A Phase I Study of 225Ac-Lintuzumab in Patients With Multiple Myeloma Progressing After . 3 Prior Anti-MM Regimens or Refractory to QUAD (Carfilzomib, Lenalidomide, Pomalidomide, and Dexamethasone)
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Lintuzumab Ac-225 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Actinium Pharmaceuticals
- 13 Sep 2017 According to an Actinium Pharmaceuticals media release, updates from the study will be presented at the Society of Hematologic Oncology 2017 Annual Meeting (SOHO).
- 15 Jun 2017 According to an Actinium Pharmaceuticals media release, the company expects to readout topline data from this study in 2018.
- 22 Dec 2016 New trial record